News & Events about G1 Therapeutics Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, G1s Chief Executive Officer Jack Bailey will provide a corporate presentation during the virtual ...
Globe Newswire
2 months ago
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 14,400 shares of G1s common stock and 9,400 restricted stock units (RSUs) to five hired ...
Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS) Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS) PR Newswire VANCOUVER, British Colombia, Nov. 30, 2022 FN Media Group Presents USA News Group News Commentary...
G1 Therapeutics (NASDAQ:GTHX Get Rating) had its target price cut by investment analysts at HC Wainwright from $57.00 to $34.00 in a research note issued to investors on Wednesday, The Fly reports. HC Wainwrights price objective points to a potential upside of 455.56% from the stocks previous close...
Ticker Report
2 months ago
G1 Therapeutics (NASDAQ:GTHX Get Rating) had its price objective cut by HC Wainwright from $57.00 to $34.00 in a research note issued on Wednesday, The Fly reports. HC Wainwrights price target points to a potential upside of 455.56% from the stocks previous close. GTHX has been...